Equities

Dechra Pharmaceuticals PLC

Dechra Pharmaceuticals PLC

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (GBX)2,748.00
  • Today's Change4.00 / 0.15%
  • Shares traded64.78k
  • 1 Year change0.15%
  • Beta0.6418
Data delayed at least 20 minutes, as of May 24 2019 16:35 BST.
More ▼

Key statistics

On Friday, Dechra Pharmaceuticals PLC (DPH:LSE) closed at 2,748.00, -13.60% below its 52-week high of 3,180.48, set on Aug 14, 2018.
52-week range
Today
1,992.00Nov 20 20183,180.48Aug 14 2018
Markit short selling activity
Low
Med
High
Open2,736.00
High2,772.00
Low2,736.00
Bid--
Offer--
Previous close2,744.00
Average volume170.44k
Shares outstanding102.63m
Free float97.24m
P/E (TTM)109.97
Market cap2.82bn GBP
EPS (TTM)0.2499
GBP
Annual div (ADY)27.67
GBX
Annual div yield (ADY)1.01%
Div ex-dateMar 07 2019
Div pay-dateApr 08 2019
Data delayed at least 20 minutes, as of May 24 2019 16:35 BST.
More ▼

Investors Chronicle View

The last IC recommendation on Dechra Pharmaceuticals PLC shares was Hold at 2,470.00 on 25 Feb 2019Read the full article

Board of Directors

1/8

Tony Rice, Non-Executive Chairman

2/8

Ian Page, Chief Executive Officer

3/8

Tony Griffin, Managing Director, Dechra Veterinary Products EU

4/8

Ishbel Macpherson, Senior Independent Non-Executive Director

5/8

Julian Heslop, Non-Executive Director

6/8

Dr Lawson Macartney, Non-Executive Director

7/8

Lisa Bright, Non-Executive Director

8/8

Paul Sandland, Acting Chief Financial Officer

Contact

Address:
Dechra Pharmaceuticals PLC
24 Cheshire Avenue
Cheshire Business Park
Lostock Gralam
Northwich
CW9 7UA

T: +44 (0) 1606 814730
F: +44 (0) 1606 814731
E: corporate.enquiries@dechra.com

Financial PR Advisors:
TooleyStreet Communications
Regency Court
68 Caroline Street
Birmingham
B3 3SF

Chief Executive Officer: Ian Page
E: corporate.enquiries@dechra.com
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.